{"results":[{"description":"Administration of parenteral nutrition without a filter has been associated with a number of adverse incidents including an embolism which resulted in a fatal outcome. ","format":"drug_safety_update","link":"/drug-safety-update/filters-should-be-used-during-the-administration-of-parenteral-nutrition-for-patients-in-all-care-settings","organisations":[{"organisation_type":"executive_agency","organisation_state":"live","superseding_organisations":[],"acronym":"MHRA","content_id":"240f72bd-9a4d-4f39-94d9-77235cadde8e","link":"/government/organisations/medicines-and-healthcare-products-regulatory-agency","parent_organisations":["department-of-health-and-social-care"],"superseded_organisations":[],"analytics_identifier":"EA63","title":"Medicines and Healthcare products Regulatory Agency","organisation_crest":"single-identity","organisation_brand":"department-of-health-social-care","child_organisations":[],"logo_formatted_title":"Medicines &amp; Healthcare products<br/>Regulatory Agency","slug":"medicines-and-healthcare-products-regulatory-agency","public_timestamp":"2025-06-25T11:21:52Z"}],"public_timestamp":"2026-09-02T10:00:02Z","title":"Filters should be used during the administration of Parenteral Nutrition for patients in all care settings","topical_events":[],"organisation_content_ids":["240f72bd-9a4d-4f39-94d9-77235cadde8e"],"expanded_organisations":[{"organisation_type":"executive_agency","organisation_state":"live","superseding_organisations":[],"acronym":"MHRA","content_id":"240f72bd-9a4d-4f39-94d9-77235cadde8e","link":"/government/organisations/medicines-and-healthcare-products-regulatory-agency","parent_organisations":["department-of-health-and-social-care"],"superseded_organisations":[],"analytics_identifier":"EA63","title":"Medicines and Healthcare products Regulatory Agency","organisation_crest":"single-identity","organisation_brand":"department-of-health-social-care","child_organisations":[],"logo_formatted_title":"Medicines &amp; Healthcare products<br/>Regulatory Agency","slug":"medicines-and-healthcare-products-regulatory-agency","public_timestamp":"2025-06-25T11:21:52Z"}],"index":"govuk","es_score":null,"_id":"/drug-safety-update/filters-should-be-used-during-the-administration-of-parenteral-nutrition-for-patients-in-all-care-settings","elasticsearch_type":"drug_safety_update","document_type":"drug_safety_update"},{"description":"Decreased vitamin B12 levels, or vitamin B12 deficiency, is now considered to be a common side effect in patients on metformin treatment, especially in those receiving a higher dose or longer treatment duration and in those with existing risk factors. We are therefore advising checking vitamin B12 serum levels in patients being treated with metformin who have symptoms suggestive of vitamin B12 deficiency. We also advise that periodic monitoring for patients with risk factors for vitamin B12 deficiency should be considered.","format":"drug_safety_update","link":"/drug-safety-update/metformin-and-reduced-vitamin-b12-levels-new-advice-for-monitoring-patients-at-risk","organisations":[{"organisation_type":"executive_agency","organisation_state":"live","superseding_organisations":[],"acronym":"MHRA","content_id":"240f72bd-9a4d-4f39-94d9-77235cadde8e","link":"/government/organisations/medicines-and-healthcare-products-regulatory-agency","parent_organisations":["department-of-health-and-social-care"],"superseded_organisations":[],"analytics_identifier":"EA63","title":"Medicines and Healthcare products Regulatory Agency","organisation_crest":"single-identity","organisation_brand":"department-of-health-social-care","child_organisations":[],"logo_formatted_title":"Medicines &amp; Healthcare products<br/>Regulatory Agency","slug":"medicines-and-healthcare-products-regulatory-agency","public_timestamp":"2025-06-25T11:21:52Z"}],"public_timestamp":"2022-06-20T15:39:03Z","title":"Metformin and reduced vitamin B12 levels: new advice for monitoring patients at risk","topical_events":[],"organisation_content_ids":["240f72bd-9a4d-4f39-94d9-77235cadde8e"],"expanded_organisations":[{"organisation_type":"executive_agency","organisation_state":"live","superseding_organisations":[],"acronym":"MHRA","content_id":"240f72bd-9a4d-4f39-94d9-77235cadde8e","link":"/government/organisations/medicines-and-healthcare-products-regulatory-agency","parent_organisations":["department-of-health-and-social-care"],"superseded_organisations":[],"analytics_identifier":"EA63","title":"Medicines and Healthcare products Regulatory Agency","organisation_crest":"single-identity","organisation_brand":"department-of-health-social-care","child_organisations":[],"logo_formatted_title":"Medicines &amp; Healthcare products<br/>Regulatory Agency","slug":"medicines-and-healthcare-products-regulatory-agency","public_timestamp":"2025-06-25T11:21:52Z"}],"index":"govuk","es_score":null,"_id":"/drug-safety-update/metformin-and-reduced-vitamin-b12-levels-new-advice-for-monitoring-patients-at-risk","elasticsearch_type":"drug_safety_update","document_type":"drug_safety_update"},{"description":"The MHRA has reviewed the evidence for finasteride and dutasteride and the risk of suicidal thoughts and behaviours and has recommended further measures to minimise this risk. ","format":"drug_safety_update","link":"/drug-safety-update/finasteride-and-dutasteride-updated-safety-warnings-for-psychiatric-side-effects-and-sexual-dysfunction","organisations":[{"organisation_type":"executive_agency","organisation_state":"live","superseding_organisations":[],"acronym":"MHRA","content_id":"240f72bd-9a4d-4f39-94d9-77235cadde8e","link":"/government/organisations/medicines-and-healthcare-products-regulatory-agency","parent_organisations":["department-of-health-and-social-care"],"superseded_organisations":[],"analytics_identifier":"EA63","title":"Medicines and Healthcare products Regulatory Agency","organisation_crest":"single-identity","organisation_brand":"department-of-health-social-care","child_organisations":[],"logo_formatted_title":"Medicines &amp; Healthcare products<br/>Regulatory Agency","slug":"medicines-and-healthcare-products-regulatory-agency","public_timestamp":"2025-06-25T11:21:52Z"}],"public_timestamp":"2026-05-11T13:29:47Z","title":"Finasteride and Dutasteride – updated safety warnings for psychiatric side effects and sexual dysfunction","topical_events":[],"organisation_content_ids":["240f72bd-9a4d-4f39-94d9-77235cadde8e"],"expanded_organisations":[{"organisation_type":"executive_agency","organisation_state":"live","superseding_organisations":[],"acronym":"MHRA","content_id":"240f72bd-9a4d-4f39-94d9-77235cadde8e","link":"/government/organisations/medicines-and-healthcare-products-regulatory-agency","parent_organisations":["department-of-health-and-social-care"],"superseded_organisations":[],"analytics_identifier":"EA63","title":"Medicines and Healthcare products Regulatory Agency","organisation_crest":"single-identity","organisation_brand":"department-of-health-social-care","child_organisations":[],"logo_formatted_title":"Medicines &amp; Healthcare products<br/>Regulatory Agency","slug":"medicines-and-healthcare-products-regulatory-agency","public_timestamp":"2025-06-25T11:21:52Z"}],"index":"govuk","es_score":null,"_id":"/drug-safety-update/finasteride-and-dutasteride-updated-safety-warnings-for-psychiatric-side-effects-and-sexual-dysfunction","elasticsearch_type":"drug_safety_update","document_type":"drug_safety_update"},{"description":"Quinine should only be considered when cramps cause regular disruption of sleep. ","format":"drug_safety_update","link":"/drug-safety-update/quinine-not-to-be-used-routinely-for-nocturnal-leg-cramps","organisations":[{"organisation_type":"executive_agency","organisation_state":"live","superseding_organisations":[],"acronym":"MHRA","content_id":"240f72bd-9a4d-4f39-94d9-77235cadde8e","link":"/government/organisations/medicines-and-healthcare-products-regulatory-agency","parent_organisations":["department-of-health-and-social-care"],"superseded_organisations":[],"analytics_identifier":"EA63","title":"Medicines and Healthcare products Regulatory Agency","organisation_crest":"single-identity","organisation_brand":"department-of-health-social-care","child_organisations":[],"logo_formatted_title":"Medicines &amp; Healthcare products<br/>Regulatory Agency","slug":"medicines-and-healthcare-products-regulatory-agency","public_timestamp":"2025-06-25T11:21:52Z"}],"public_timestamp":"2014-12-11T14:29:10Z","title":"Quinine: not to be used routinely for nocturnal leg cramps","topical_events":[],"organisation_content_ids":["240f72bd-9a4d-4f39-94d9-77235cadde8e"],"expanded_organisations":[{"organisation_type":"executive_agency","organisation_state":"live","superseding_organisations":[],"acronym":"MHRA","content_id":"240f72bd-9a4d-4f39-94d9-77235cadde8e","link":"/government/organisations/medicines-and-healthcare-products-regulatory-agency","parent_organisations":["department-of-health-and-social-care"],"superseded_organisations":[],"analytics_identifier":"EA63","title":"Medicines and Healthcare products Regulatory Agency","organisation_crest":"single-identity","organisation_brand":"department-of-health-social-care","child_organisations":[],"logo_formatted_title":"Medicines &amp; Healthcare products<br/>Regulatory Agency","slug":"medicines-and-healthcare-products-regulatory-agency","public_timestamp":"2025-06-25T11:21:52Z"}],"index":"govuk","es_score":null,"_id":"/drug-safety-update/quinine-not-to-be-used-routinely-for-nocturnal-leg-cramps","elasticsearch_type":"drug_safety_update","document_type":"drug_safety_update"},{"description":"Healthcare professionals should be aware of the potential for delayed onset of angioedema and the distinction between bradykinin- and histamine-mediated cases, as treatment strategies differ significantly and bradykinin-mediated angioedema does not respond to standard treatment.","format":"drug_safety_update","link":"/drug-safety-update/ace-inhibitors-be-aware-of-the-distinction-between-bradykinin-and-histamine-mediated-angioedema-as-treatment-strategies-differ-significantly","organisations":[{"organisation_type":"executive_agency","organisation_state":"live","superseding_organisations":[],"acronym":"MHRA","content_id":"240f72bd-9a4d-4f39-94d9-77235cadde8e","link":"/government/organisations/medicines-and-healthcare-products-regulatory-agency","parent_organisations":["department-of-health-and-social-care"],"superseded_organisations":[],"analytics_identifier":"EA63","title":"Medicines and Healthcare products Regulatory Agency","organisation_crest":"single-identity","organisation_brand":"department-of-health-social-care","child_organisations":[],"logo_formatted_title":"Medicines &amp; Healthcare products<br/>Regulatory Agency","slug":"medicines-and-healthcare-products-regulatory-agency","public_timestamp":"2025-06-25T11:21:52Z"}],"public_timestamp":"2026-06-16T13:06:19Z","title":"ACE-inhibitors: Be aware of the distinction between bradykinin- and histamine-mediated angioedema, as treatment strategies differ significantly ","topical_events":[],"organisation_content_ids":["240f72bd-9a4d-4f39-94d9-77235cadde8e"],"expanded_organisations":[{"organisation_type":"executive_agency","organisation_state":"live","superseding_organisations":[],"acronym":"MHRA","content_id":"240f72bd-9a4d-4f39-94d9-77235cadde8e","link":"/government/organisations/medicines-and-healthcare-products-regulatory-agency","parent_organisations":["department-of-health-and-social-care"],"superseded_organisations":[],"analytics_identifier":"EA63","title":"Medicines and Healthcare products Regulatory Agency","organisation_crest":"single-identity","organisation_brand":"department-of-health-social-care","child_organisations":[],"logo_formatted_title":"Medicines &amp; Healthcare products<br/>Regulatory Agency","slug":"medicines-and-healthcare-products-regulatory-agency","public_timestamp":"2025-06-25T11:21:52Z"}],"index":"govuk","es_score":null,"_id":"/drug-safety-update/ace-inhibitors-be-aware-of-the-distinction-between-bradykinin-and-histamine-mediated-angioedema-as-treatment-strategies-differ-significantly","elasticsearch_type":"drug_safety_update","document_type":"drug_safety_update"},{"description":"We inform healthcare professionals that the Medicines and Healthcare products Regulatory Agency (MHRA) has launched new guidance to highlight the latest safety advice on the steps to take during anaphylaxis. This new guidance includes an easy step-by-step guide on what to do in an emergency and provides updated advice on body positioning.","format":"drug_safety_update","link":"/drug-safety-update/adrenaline-auto-injectors-aais-new-guidance-and-resources-for-safe-use","organisations":[{"organisation_type":"executive_agency","organisation_state":"live","superseding_organisations":[],"acronym":"MHRA","content_id":"240f72bd-9a4d-4f39-94d9-77235cadde8e","link":"/government/organisations/medicines-and-healthcare-products-regulatory-agency","parent_organisations":["department-of-health-and-social-care"],"superseded_organisations":[],"analytics_identifier":"EA63","title":"Medicines and Healthcare products Regulatory Agency","organisation_crest":"single-identity","organisation_brand":"department-of-health-social-care","child_organisations":[],"logo_formatted_title":"Medicines &amp; Healthcare products<br/>Regulatory Agency","slug":"medicines-and-healthcare-products-regulatory-agency","public_timestamp":"2025-06-25T11:21:52Z"}],"public_timestamp":"2023-06-27T12:35:03Z","title":"Adrenaline auto-injectors (AAIs): new guidance and resources for safe use","topical_events":[],"organisation_content_ids":["240f72bd-9a4d-4f39-94d9-77235cadde8e"],"expanded_organisations":[{"organisation_type":"executive_agency","organisation_state":"live","superseding_organisations":[],"acronym":"MHRA","content_id":"240f72bd-9a4d-4f39-94d9-77235cadde8e","link":"/government/organisations/medicines-and-healthcare-products-regulatory-agency","parent_organisations":["department-of-health-and-social-care"],"superseded_organisations":[],"analytics_identifier":"EA63","title":"Medicines and Healthcare products Regulatory Agency","organisation_crest":"single-identity","organisation_brand":"department-of-health-social-care","child_organisations":[],"logo_formatted_title":"Medicines &amp; Healthcare products<br/>Regulatory Agency","slug":"medicines-and-healthcare-products-regulatory-agency","public_timestamp":"2025-06-25T11:21:52Z"}],"index":"govuk","es_score":null,"_id":"/drug-safety-update/adrenaline-auto-injectors-aais-new-guidance-and-resources-for-safe-use","elasticsearch_type":"drug_safety_update","document_type":"drug_safety_update"},{"description":"New maximum daily dose restrictions (including in elderly patients), contraindications, and warnings.","format":"drug_safety_update","link":"/drug-safety-update/citalopram-and-escitalopram-qt-interval-prolongation","organisations":[{"organisation_type":"executive_agency","organisation_state":"live","superseding_organisations":[],"acronym":"MHRA","content_id":"240f72bd-9a4d-4f39-94d9-77235cadde8e","link":"/government/organisations/medicines-and-healthcare-products-regulatory-agency","parent_organisations":["department-of-health-and-social-care"],"superseded_organisations":[],"analytics_identifier":"EA63","title":"Medicines and Healthcare products Regulatory Agency","organisation_crest":"single-identity","organisation_brand":"department-of-health-social-care","child_organisations":[],"logo_formatted_title":"Medicines &amp; Healthcare products<br/>Regulatory Agency","slug":"medicines-and-healthcare-products-regulatory-agency","public_timestamp":"2025-06-25T11:21:52Z"}],"public_timestamp":"2014-12-11T14:32:21Z","title":"Citalopram and escitalopram: QT interval prolongation","topical_events":[],"organisation_content_ids":["240f72bd-9a4d-4f39-94d9-77235cadde8e"],"expanded_organisations":[{"organisation_type":"executive_agency","organisation_state":"live","superseding_organisations":[],"acronym":"MHRA","content_id":"240f72bd-9a4d-4f39-94d9-77235cadde8e","link":"/government/organisations/medicines-and-healthcare-products-regulatory-agency","parent_organisations":["department-of-health-and-social-care"],"superseded_organisations":[],"analytics_identifier":"EA63","title":"Medicines and Healthcare products Regulatory Agency","organisation_crest":"single-identity","organisation_brand":"department-of-health-social-care","child_organisations":[],"logo_formatted_title":"Medicines &amp; Healthcare products<br/>Regulatory Agency","slug":"medicines-and-healthcare-products-regulatory-agency","public_timestamp":"2025-06-25T11:21:52Z"}],"index":"govuk","es_score":null,"_id":"/drug-safety-update/citalopram-and-escitalopram-qt-interval-prolongation","elasticsearch_type":"drug_safety_update","document_type":"drug_safety_update"},{"description":"Systemic fluoroquinolones must now only be prescribed when other commonly recommended antibiotics are inappropriate. This follows a review by the MHRA which looked at the effectiveness of current measures to reduce the identified risk of disabling and potentially long-lasting or irreversible side effects.","format":"drug_safety_update","link":"/drug-safety-update/fluoroquinolone-antibiotics-must-now-only-be-prescribed-when-other-commonly-recommended-antibiotics-are-inappropriate","organisations":[{"organisation_type":"executive_agency","organisation_state":"live","superseding_organisations":[],"acronym":"MHRA","content_id":"240f72bd-9a4d-4f39-94d9-77235cadde8e","link":"/government/organisations/medicines-and-healthcare-products-regulatory-agency","parent_organisations":["department-of-health-and-social-care"],"superseded_organisations":[],"analytics_identifier":"EA63","title":"Medicines and Healthcare products Regulatory Agency","organisation_crest":"single-identity","organisation_brand":"department-of-health-social-care","child_organisations":[],"logo_formatted_title":"Medicines &amp; Healthcare products<br/>Regulatory Agency","slug":"medicines-and-healthcare-products-regulatory-agency","public_timestamp":"2025-06-25T11:21:52Z"}],"public_timestamp":"2024-01-22T15:41:07Z","title":"Fluoroquinolone antibiotics: must now only be prescribed when other commonly recommended antibiotics are inappropriate","topical_events":[],"organisation_content_ids":["240f72bd-9a4d-4f39-94d9-77235cadde8e"],"expanded_organisations":[{"organisation_type":"executive_agency","organisation_state":"live","superseding_organisations":[],"acronym":"MHRA","content_id":"240f72bd-9a4d-4f39-94d9-77235cadde8e","link":"/government/organisations/medicines-and-healthcare-products-regulatory-agency","parent_organisations":["department-of-health-and-social-care"],"superseded_organisations":[],"analytics_identifier":"EA63","title":"Medicines and Healthcare products Regulatory Agency","organisation_crest":"single-identity","organisation_brand":"department-of-health-social-care","child_organisations":[],"logo_formatted_title":"Medicines &amp; Healthcare products<br/>Regulatory Agency","slug":"medicines-and-healthcare-products-regulatory-agency","public_timestamp":"2025-06-25T11:21:52Z"}],"index":"govuk","es_score":null,"_id":"/drug-safety-update/fluoroquinolone-antibiotics-must-now-only-be-prescribed-when-other-commonly-recommended-antibiotics-are-inappropriate","elasticsearch_type":"drug_safety_update","document_type":"drug_safety_update"},{"description":"The product information has been updated for all domperidone products, to include a contraindication for patients with confirmed or suspected phaeochromocytoma (a rare tumour of the adrenal gland), due to the risk of episodes of severe hypertension. ","format":"drug_safety_update","link":"/drug-safety-update/domperidone-new-contraindication-in-patients-with-phaeochromocytoma-due-to-the-risk-of-severe-hypertension","organisations":[{"organisation_type":"executive_agency","organisation_state":"live","superseding_organisations":[],"acronym":"MHRA","content_id":"240f72bd-9a4d-4f39-94d9-77235cadde8e","link":"/government/organisations/medicines-and-healthcare-products-regulatory-agency","parent_organisations":["department-of-health-and-social-care"],"superseded_organisations":[],"analytics_identifier":"EA63","title":"Medicines and Healthcare products Regulatory Agency","organisation_crest":"single-identity","organisation_brand":"department-of-health-social-care","child_organisations":[],"logo_formatted_title":"Medicines &amp; Healthcare products<br/>Regulatory Agency","slug":"medicines-and-healthcare-products-regulatory-agency","public_timestamp":"2025-06-25T11:21:52Z"}],"public_timestamp":"2026-07-21T13:00:37Z","title":"Domperidone: new contraindication in patients with phaeochromocytoma due to the risk of severe hypertension","topical_events":[],"organisation_content_ids":["240f72bd-9a4d-4f39-94d9-77235cadde8e"],"expanded_organisations":[{"organisation_type":"executive_agency","organisation_state":"live","superseding_organisations":[],"acronym":"MHRA","content_id":"240f72bd-9a4d-4f39-94d9-77235cadde8e","link":"/government/organisations/medicines-and-healthcare-products-regulatory-agency","parent_organisations":["department-of-health-and-social-care"],"superseded_organisations":[],"analytics_identifier":"EA63","title":"Medicines and Healthcare products Regulatory Agency","organisation_crest":"single-identity","organisation_brand":"department-of-health-social-care","child_organisations":[],"logo_formatted_title":"Medicines &amp; Healthcare products<br/>Regulatory Agency","slug":"medicines-and-healthcare-products-regulatory-agency","public_timestamp":"2025-06-25T11:21:52Z"}],"index":"govuk","es_score":null,"_id":"/drug-safety-update/domperidone-new-contraindication-in-patients-with-phaeochromocytoma-due-to-the-risk-of-severe-hypertension","elasticsearch_type":"drug_safety_update","document_type":"drug_safety_update"},{"description":"Healthcare professionals prescribing fluoroquinolone antibiotics (ciprofloxacin, delafloxacin, levofloxacin, moxifloxacin, ofloxacin) are reminded to be alert to the risk of disabling and potentially long-lasting or irreversible side effects. Do not prescribe fluoroquinolones for non-severe or self-limiting infections, or for mild to moderate infections (such as in acute exacerbation of chronic bronchitis and chronic obstructive pulmonary disease) unless other antibiotics that are commonly recommended for these infections are considered inappropriate. Fluoroquinolone treatment should be discontinued at the first signs of a serious adverse reaction, including tendon pain or inflammation.  ","format":"drug_safety_update","link":"/drug-safety-update/fluoroquinolone-antibiotics-reminder-of-the-risk-of-disabling-and-potentially-long-lasting-or-irreversible-side-effects","organisations":[{"organisation_type":"executive_agency","organisation_state":"live","superseding_organisations":[],"acronym":"MHRA","content_id":"240f72bd-9a4d-4f39-94d9-77235cadde8e","link":"/government/organisations/medicines-and-healthcare-products-regulatory-agency","parent_organisations":["department-of-health-and-social-care"],"superseded_organisations":[],"analytics_identifier":"EA63","title":"Medicines and Healthcare products Regulatory Agency","organisation_crest":"single-identity","organisation_brand":"department-of-health-social-care","child_organisations":[],"logo_formatted_title":"Medicines &amp; Healthcare products<br/>Regulatory Agency","slug":"medicines-and-healthcare-products-regulatory-agency","public_timestamp":"2025-06-25T11:21:52Z"}],"public_timestamp":"2023-08-30T09:48:23Z","title":"Fluoroquinolone antibiotics: reminder of the risk of disabling and potentially long-lasting or irreversible side effects","topical_events":[],"organisation_content_ids":["240f72bd-9a4d-4f39-94d9-77235cadde8e"],"expanded_organisations":[{"organisation_type":"executive_agency","organisation_state":"live","superseding_organisations":[],"acronym":"MHRA","content_id":"240f72bd-9a4d-4f39-94d9-77235cadde8e","link":"/government/organisations/medicines-and-healthcare-products-regulatory-agency","parent_organisations":["department-of-health-and-social-care"],"superseded_organisations":[],"analytics_identifier":"EA63","title":"Medicines and Healthcare products Regulatory Agency","organisation_crest":"single-identity","organisation_brand":"department-of-health-social-care","child_organisations":[],"logo_formatted_title":"Medicines &amp; Healthcare products<br/>Regulatory Agency","slug":"medicines-and-healthcare-products-regulatory-agency","public_timestamp":"2025-06-25T11:21:52Z"}],"index":"govuk","es_score":null,"_id":"/drug-safety-update/fluoroquinolone-antibiotics-reminder-of-the-risk-of-disabling-and-potentially-long-lasting-or-irreversible-side-effects","elasticsearch_type":"drug_safety_update","document_type":"drug_safety_update"}],"total":867,"start":0,"aggregates":{},"suggested_queries":[],"suggested_autocomplete":[],"es_cluster":"A"}